PMID- 15820063
OWN - NLM
STAT- MEDLINE
DCOM- 20060720
LR  - 20231213
VI  - 24
IP  - 4
DP  - 2005 Apr
TI  - [In vitro anti-leukemia activity of cord blood original cytotoxic T lymphocytes].
PG  - 419-24
AB  - BACKGROUND & OBJECTIVE: Cord blood transplantation (CBT) possesses 
      graft-versus-leukemia (GVL) effect. It is possible to cure leukemia if specific 
      cytotoxic T lymphocytes (CTLs) can be induced from lymphocytes in cord blood 
      (CB), and be used to eradicate minimal residual disease (MRD) in leukemia 
      patients. This study was to induce CTLs from cord blood, and explore its in vitro 
      anti-leukemia activity. METHODS: Dendritic cells (DCs) were generated from 8 
      samples of cord blood mononuclear cells by culturing with multiple cytokines. 
      Immature DCs were pulsed with apoptotic leukemia cells to present leukemic 
      antigens to cord blood original lymphocytes to obtain CTLs. The characteristics 
      of maturation of DCs were evaluated by morphology and flow cytometry. 
      Anti-leukemia effect of CTLs was measured by lactate dehydrogenase release assay. 
      RESULTS: Typical DCs were induced from all of the 8 samples. Expressions of 
      immunologic markers CD1a(+), HLA-DR(+), CD86(+), CD83(+) on DCs were 
      significantly higher after culturing than before culturing [(29.6+/-13.8)% vs. 
      (1.8+/-1.9)%, (81.1+/-17.8)% vs. (19.4+/-10.6)%, (42.7+/-21.9)% vs. (7.5+/-5.3)%, 
      (8.0+/-6.9)% vs. (1.4+/-1.1)%, respectively, P< 0.05]. When E:T ratio was 50:1, 
      CTLs showed far higher cytotoxicity to uncultured acute myeloid leukemia (AML) 
      cells than to K562 cells, and to mononuclear cells of bone marrow from the 
      corresponding patients in complete remission phase (CR-MNCs) [(52.6+/-21.0)% vs. 
      (18.2+/-20.2)%, and (3.3+/-6.3)%, P < 0.05]. CONCLUSIONS: Mature DCs derived from 
      cord blood, which loaded leukemia antigens, could induce leukemia-specific CTLs. 
      The CTLs have vigorous cytotoxicity to original leukemia cells rather than 
      CR-MNCs.
FAU - Zeng, Lin-Juan
AU  - Zeng LJ
AD  - Oncology and Hematology Center, The First Affiliated Hospital, Guangzhou Medical 
      College, Guangzhou, Guangdong, 510230, P. R. China. tanhuo@public.gd.cn.
FAU - Tan, Huo
AU  - Tan H
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD1)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD1a antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Immunoglobulins)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigen Presentation/*immunology
MH  - Antigens, CD/analysis
MH  - Antigens, CD1/analysis
MH  - Apoptosis/immunology
MH  - B7-2 Antigen/analysis
MH  - Cells, Cultured
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Fetal Blood/*immunology
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Immunoglobulins/analysis
MH  - Immunophenotyping
MH  - Leukemia, Myeloid, Acute/*immunology/pathology
MH  - Leukocytes, Mononuclear/cytology
MH  - Male
MH  - Membrane Glycoproteins/analysis
MH  - Middle Aged
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - CD83 Antigen
EDAT- 2005/04/12 09:00
MHDA- 2006/07/21 09:00
CRDT- 2005/04/12 09:00
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2006/07/21 09:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
AID - 1000467X2005040419 [pii]
PST - ppublish
SO  - Ai Zheng. 2005 Apr;24(4):419-24.